Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Rev-5901. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.98 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.98 |
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.98 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.98 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.98 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.98 |
| ▸ | TP53 | P04637 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rev-5901 SCHEMBL678489 | 0.99 | GPBAR1 (1.00) | CYSLTR1GPBAR1CYSLTR2MAPK1ALOX5 | |
| Rev-5901 SCHEMBL29369872 | 0.99 | GPBAR1 (1.00) | CYSLTR1GPBAR1CYSLTR2MAPK1ALOX5 | |
| SCHEMBL10638786 | 0.98 | CYSLTR1 (0.98) | CYSLTR1GPBAR1CYSLTR2MAPK1ALOX5 | |
| Rev-5901 SCHEMBL10873776 | 0.97 | CYSLTR1 (0.96) | CYSLTR1GPBAR1CYSLTR2MAPK1ALOX5 | |
| Rev-5901 SCHEMBL4348786 | 0.97 | CYSLTR1 (0.96) | CYSLTR1GPBAR1CYSLTR2MAPK1ALOX5 | |
| Rev-5901 SCHEMBL10827442 | 0.97 | CYSLTR1 (0.96) | CYSLTR1GPBAR1CYSLTR2MAPK1ALOX5 | |
| SCHEMBL10769450 | 0.96 | CYSLTR1 (0.94) | CYSLTR1GPBAR1CYSLTR2MAPK1ALOX5 | |
| SCHEMBL7751090 | 0.88 | CYSLTR1 (0.80) | CYSLTR1GPBAR1CYSLTR2MAPK1ALOX5 | |
| SCHEMBL10639082 | 0.88 | CYSLTR1 (0.80) | CYSLTR1GPBAR1CYSLTR2MAPK1ALOX5 | |
| SCHEMBL10638680 | 0.87 | GPBAR1 (0.78) | CYSLTR1GPBAR1CYSLTR2MAPK1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6099834-A | Method for modulating eicosanoid mediated immune responses in arthropods | BOARD OF REGENTS UNIVERSITY OF NEBRASKA-LINCOLN (US) | 2000-08-08 | — | — | US | claimed |
| EP-0234500-A1 | Antiasthma inhalation compositions | RORER PHARMACEUTICAL CORPORATION (US) | 1987-09-02 | — | — | EP | claimed |
| EP-0181568-A2 | Anti-inflammatory/anti-allergic compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1986-05-21 | — | — | EP | claimed |
| US-4567184-A | Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies | USV PHARMACEUTICAL CORPORATION (US) | 1986-01-28 | — | — | US | claimed |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | disclosed |
| US-12233071-B2 | Medicament for treating cough | NIPPON CHEMIPHAR CO., LTD. (JP) | 2025-02-25 | — | — | US | disclosed |
| EP-4501357-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | Takasaki University of Health and Welfare (JP) | 2025-02-05 | — | — | EP | disclosed |
| CN-119233829-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy | 学校法人高崎健康福祉大学 | 2024-12-31 | — | — | CN | disclosed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | disclosed |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-09-07 | — | — | US | disclosed |
| US-20230248738-A1 | MEDICAMENT FOR TREATING COUGH | NIPPON CHEMIPHAR CO., LTD (JP) | 2023-08-10 | — | — | US | disclosed |
| US-11666582-B2 | Medicament for treating cough | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-06-06 | — | — | US | disclosed |
| US-6617345-B1 | Cyclooxygenase-2 inhibitor is (5-bromo-2-(4-fluorophenyl )-3-(4-(methylsulfonyl)phey)-thiophene), N-(2-(cyclohexyloxy 4-nitrophenyl)-methanesulfonamide), meloxicam, flosulide or cyclic substituted phenyl sulfones or sulfonamides | G.D. SEARLE & CO. | 2003-09-09 | — | — | US | disclosed |
| US-6099834-A | Method for modulating eicosanoid mediated immune responses in arthropods | BOARD OF REGENTS UNIVERSITY OF NEBRASKA-LINCOLN (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0110405-B1 | ANTIINFLAMMATORY/ANTIALLERGIC COMPOUNDS | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1990-12-27 | — | — | EP | disclosed |
| US-4794188-A | LIPOXYGENASE INHIBITORS | USV PHARMACEUTICAL CORPORATION (US) | 1988-12-27 | — | — | US | disclosed |
| EP-0234500-A1 | Antiasthma inhalation compositions | RORER PHARMACEUTICAL CORPORATION (US) | 1987-09-02 | — | — | EP | disclosed |
| US-4567184-A | Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies | USV PHARMACEUTICAL CORPORATION (US) | 1986-01-28 | — | — | US | disclosed |
| EP-0110405-A2 | Antiinflammatory/antiallergic compounds | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1984-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233071-B2 | Medicament for treating cough | P2RX4, P2RX3, P2RX5 | PTGS1 261/4885PTGS2 397/4885CYSLTR1 65/4885 |
| US-11666582-B2 | Medicament for treating cough | P2RX4, P2RX3, P2RX5 | PTGS1 261/4885PTGS2 397/4885CYSLTR1 65/4885 |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | HRH2, HRH4, HRH1 | PTGS1 104/4885PTGS2 200/4885CYSLTR1 31/4885 |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TRPV1, TRPV4, TRPV5 | PTGS1 150/4885PTGS2 365/4885CYSLTR1 28/4885 |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | P2RX5, P2RX3, P2RX2 | PTGS1 244/4885PTGS2 413/4885CYSLTR1 39/4885 |
| US-20230248738-A1 | MEDICAMENT FOR TREATING COUGH | P2RX4, P2RX3, P2RX5 | PTGS1 261/4885PTGS2 397/4885CYSLTR1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.